Solstice Air News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Honeywell and global contract development and manufacturing organisation (CDMO) Recipharm have announced a commercial partnership that will speed up the development of pressurised metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant. As many as 384 million people globally suffer from chronic obstructive pulmonary disease (COPD), and about 262 million people suffer from asthma. Many of these patients are treated using pMDIs that have a high global warming potential due to the use of hydrofluoroalkanes (HFAs) as propellants. Honeywell So...

Partnership aims to ramp up production of Honeywell's Solstice Air asthma inhalers which use 'near-zero' climate-warming gases HFAs

Honeywell, an industry solutions company that provides a range of products, has teamed up with global contract development and manufacturing organization Recipharm to develop pressurized metered dose inhalers that use Honeywell's near-zero global warming potential propellant.

Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care. MORRIS PLAINS, N.J. and STOCKHOLM, Aug. 17,...

Metals & mining is one of the growing applications of volatile organic compound (VOC) gas sensor its operations often involve storing hazardous materials,...